StemCell Therapy

A perfect mix of quantitative & qualitative Physical Security Servicemarket information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Physical Security Servicemarket. The study bridges the historical data from 2014 to 2019 and estimated until 2025.

The Physical Security ServiceMarket report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus Catastrophe The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of Physical Security ServiceIndustry.

Downlaod Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6335444/physical-security-service-market

The Top players are SOHGO SECURITY SERVICES CO.,LTD. (ALSOK), Bosch Sicherheitssysteme GmbH, Honeywell International,Inc., S-1 Corp, G4S P.

Market Segmentation:

Physical Security Service Market is analyzed by types like Video Surveillance, Intrusion Detection, Access Control, Othe

On the basis of the end users/applications, Transportation, Government, Banking & Finance, Utility & Energy, Residential, Manufacturing & Industrial, Othe

Download Free Sample PDF along with few company profileshttps://inforgrowth.com/sample-request/6335444/physical-security-service-market

Be the first to knock the door showing the potential that Physical Security Servicemarket is holding in it. Uncover the Gaps and Opportunities to derive the most relevant insights from our research document to gain market size.

A major chunk of this Global Physical Security ServiceMarket research report is talking about some significant approaches for enhancing the performance of the companies. Marketing strategies and different channels have been listed here. Collectively, it gives more focus on changing rules, regulations, and policies of governments. It will help to both established and new startups of the market.

The study objectives of this report are:To analyze global Physical Security Servicestatus, future forecast, growth opportunity, key market, and key players.To present the Physical Security Servicedevelopment in the United States, Europe, and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market, and key regions.

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6335444/physical-security-service-market

Major Points from Table of Contents

1 Physical Security Service Physical Security Service Market Overview2 Physical Security Service Market Competition by Manufacturers3 Production Capacity by Region4 Global Physical Security Service Market by Regions5 Production, Revenue, Price Trend by Type6 Global Physical Security Service Market Analysis by Application7 Company Profiles and Key Figures in Physical Security Service Business8 Physical Security Service Manufacturing Cost Analysis9 Marketing Channel, Distributors and Customers10 Market Dynamics11 Production and Supply Forecast12 Consumption and Demand Forecast13 Forecast by Type and by Application (2021-2026)14 Research Finding and Conclusion15 Methodology and Data Source.

ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/6335444/physical-security-service-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

See original here:
Physical Security Service Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: SOHGO SECURITY SERVICES CO.,LTD....

Visit the News Hub

Researchers seek answers to viruss mysteries, clues to possible treatments

Washington University School of Medicine in St. Louis is one of more than 30 genome sequencing hubs worldwide participating in a study to sequence the DNA of young, healthy adults and children who develop severe COVID-19 despite having no underlying medical problems. The researchers also will study people who never become infected despite repeated exposures to coronavirus. Knowledge gained from understanding COVID-19s extremes could lead to new therapeutic strategies for the illness.

To help unravel the mysteries of COVID-19, scientists are sequencing the DNA of young, healthy adults and children who develop severe illness despite having no underlying medical problems. The researchers are looking for genetic defects that could put certain individuals at high risk of becoming severely ill from the novel coronavirus.

The McDonnell Genome Institute at Washington University School of Medicine in St. Louis is one of more than 30 genome sequencing hubs worldwide participating in the study. Rheumatologist Megan A. Cooper, MD, PhD, an associate professor of pediatrics, is leading the research at Washington University. Called the COVID Human Genetic Effort, the international project is co-led by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), and Rockefeller University.

The researchers also plan to study people who never become infected with SARS-CoV-2, the virus that causes COVID-19, despite repeated exposures. Such individuals may have genetic variations that protect against infection. For example, certain rare genetic variants are known to thwart some types of viral infections, including HIV and norovirus. Knowledge gained from understanding COVID-19s extremes unusual susceptibility and resistance could lead to new therapeutic strategies for the illness.

The first focus of our study will be patients with severe responses to SARS-CoV-2 infection severe enough to require intensive care who appear otherwise healthy and are younger than 50, said Cooper, who also leads the clinical immunology program and the Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies at St. Louis Childrens Hospital.

These patients dont have uncontrolled diabetes, heart disease, chronic lung disease or any other condition that we know increases the risk of severe complications from COVID-19, she said. For example, we sometimes see stories about, say, a marathon runner or a generally fit, healthy person who nevertheless got very sick from this virus, or the few healthy children who are getting very sick with COVID-19. These are the kinds of patients were interested in for this study. A small proportion of hospitalized patients will fit this category, likely less than 10%.

Cooper studies primary immunodeficiencies in children. Primary immunodeficiencies are a group of more than 450 genetic disorders of the immune system. They often are caused by mutations in single genes that affect different aspects of immunity.

With this pandemic, we can use our skills in gene hunting to search for genes that might be associated with severe COVID-19 in children and younger adults, she said. We can foresee a future ability to do a genetic sequencing test for individual patients hospitalized with SARS-CoV-2 and get an idea of whether they are likely to need more intensive care. In the meantime, we will be able to learn a great deal about how the immune system responds to this virus and what it needs to be able to respond effectively and in an appropriate manner.

These patients genetics could reveal the important immune pathways that the body needs to fight the virus. That knowledge could lead to therapies that also could help other patients who dont have a genetic susceptibility to the virus but perhaps have high-risk conditions, such as diabetes or heart disease.

Our immune systems have never seen this virus before, Cooper said. Were seeing severe COVID-19 complications play out across the world right now. It is going to take a global effort to investigate the genetic factors and the immune system factors that really control this infection.

Research related to COVID-19, including collecting and distributing of patient samples, is managed through Washington Universitys Institute of Clinical and Translational Sciences (ICTS), led by William G. Powderly, MD, who is also the Larry J. Shapiro Director of the Institute for Public Health, the J. William Campbell Professor of Medicine and co-director of the Division of Infectious Diseases.

This research is supported by funding from the St. Louis Childrens Hospital Foundation and the Jeffrey Modell Foundation.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Here is the original post:
COVID-19 study looks at genetics of healthy people who develop severe illness - Washington University School of Medicine in St. Louis

The coronavirus has swept across the globe in recent months, and companies in all sectors of the healthcare industry have stepped up to combat the pandemic. Many are now scrambling to develop a vaccine.

One of the greatest challenges facing healthcare workers on the front lines, as well as the companies working on vaccine candidates, is that COVID-19 varies so much among patients. According to a report published by the World Health Organization back in March, approximately 80 percent of those infected exhibit mild symptoms or none at all.A study published in the journal Nature Medicine found that 44% of individuals who caught COVID-19 through secondary transmission contracted the illness while the original infector was still asymptomatic.

The most recent data released from the Centers for Disease Control and Prevention shows that 60.5 per 100,000 patients require hospitalization, and death certificates show that the flu, COVID-19, or pneumonia were behind 12.8% of all U.S. deathsfrom May 4 through May 10.Over 300,000 people worldwide have died of COVID-19.

Image source: Getty Images.

DNA testing companies are rising to the occasion with the launch of numerous studies hoping to crack the genetic code behind COVID-19. Last month, one of the biggest names in the consumer genetics market, 23andMe, initiated a study into the link between genetics and COVID-19 outcomes.

Founded in 2006, 23andMe is a privately held company that offers a slew of popular direct-to-consumer genetic tests and has the power of nearly $800 million of venture capital backing behind it. While 23andMe hasn't yet made its way to the public market, prospective investors and consumers alike should still be watching this start-up and its current study closely.

Here's what you need to know.

23andMe first launched its study back in April, and hundreds of thousands of customers have participated so far through online surveys. In the initial part of its study, 23andMe surveyed customers who had tested positive for COVID-19, as well as customers who had not received a positive diagnosis.The study will also allow contributions from family members of customers who have been ill with the coronavirus. The company will use this information to assess genetic similarities and dissimilarities among critically ill patients.

Last week, 23andMe announced that it was expanding its genetic study to include up to 10,000 adults who are not 23andMe customers and who have been hospitalized for COVID-19. In 23andMe's blog post announcing the study's expansion, the company stated that its research model means it can

not only reach out to current customers, but also quickly recruit and genotype new research participants. We can then survey those participants, and conduct genetic studies at a massive scale. ... There are several questions about whether genetics may explain the differences in immune response among patients. Our study could aid in assessing differences in risk among individuals. It could also guide efforts now under way to treat the disease caused by the virus.

When 23andMe announced its expansion of the study in a blog post published May 13, it noted that more than 500,000 people have enrolled in the study thus far, and more than 7,000 of the participants have been diagnosed with COVID-19.

In the 14 years since its founding, 23andMe has received venture-capital backing from a particularly impressive and diverse group of leading technology and pharmaceutical companies. Think big names like Fidelity Management & Research Company, Sequoia Capital, Alphabet's (NASDAQ:GOOG) Google Ventures, Johnson & Johnson's(NYSE:JNJ)venture capital division, and GlaxoSmithKline (NYSE:GSK).

23andMe is in late-stage funding. Its most recent round, in January 2019, consisted of secondary market funding from angel investor and former U.S. government official Raj Luhar. Secondary market funding occurs when an individual investor buys equity in a privately held company from current investors.

There's long been talk of 23andMe entering an initial public offering. It's possible the company could be looking to secure more late-stage funding to build its momentum before going the IPO route. A 2019 report released by private investment management firm Wellington Management Company found that

companies are staying private for longer. For example, the average age to IPO for VC-backed companies increased from 4.6 years during the 1990-2001 period to 6.4 years during the 2002-2018 period. As a result, companies are often more mature when they do go public. Businesses with market capitalization below US$1 billion have decreased as a percentage of the public market, from 53% of the Russell 2000 Index in 2005 to 23% as of 31 December 2018. Amid these changes, we recognized that the late-stage growth companies were often in need of capital to accelerate growth prior to, or in lieu of, an IPO or sale.

Many thought 23andMe would IPO back in 2015 when it secured an additional $115 million in a funding round. The company has yet to announce any definite plans to go public.

It's no secret that the consumer genetics market has faced notable headwinds over the past few years, as demand for DNA testing has dropped significantly. The reason behind this decline is not certain. It could be that the early boom in consumer interest wore off, or that privacy concerns got the better of the wider market.

In January, 23andMe laid off 14% of its employees. The company was just one in a long line of venture capital-backed entities that have had to slash their workforces in recent months. For example, one of 23andMe's top competitors, Ancestry, laid off 6% of its employees in early February. Coincidentally, Ancestry has also launched a study into the genomic aspects of COVID-19, but at present is limiting participants to existing customers only.

Naturally, there have been concerns about the fiscal future of genetic services given recent reductions in consumer demand. But with this new foray into genetic research, companies like 23andMe could be well positioned to aid medical providers and businesses in establishing new protocols both during and after the coronavirus crisis. Even though the company's IPO remains uncertain, 23andMe has solid backing and could be making some big moves in the near future. Healthcare investors should find this startup definitely worth watching over the next few years.

See the original post:
23andMe Is Trying to Crack the Genetic Code Behind the Coronavirus - Motley Fool

Each week, The Dailys Science & Tech section produces a roundup of the most exciting and influential research happening on campus or otherwise related to Stanford. Heres our digest for the week of May 1016.

A new vaccine type to prevent HIV infections

A new vaccination can provide enhanced and sustained protection against the HIV virus in rhesus macaque monkeys, a study published on May 11 in Nature Medicine found. The research might also help immunologists create a vaccine against the coronavirus and other diseases.

Most vaccines aim at stimulating serum immunity by raising antibodies to the invading pathogen, Bali Pulendran, professor of pathology and microbiology and immunology, told Stanford Medicine News. This vaccine also boosted cellular immunity, the mustering of an army of immune cells that chase down cells infected by the pathogen. We created a synergy between these two kinds of immune activity.

The adaptive immune response consists of two parts: serum immunity, including B-cells which secrete antibodies, and cellular immunity, including T-cells that find infected bodily cells and destroy them. The findings suggest vaccinations that stimulate both arms of the adaptive immune response can protect rhesus macaques from initial viral HIV infection.

These results suggest that future vaccination efforts should focus on strategies that elicit both cellular and neutralizing-antibody response, which might provide superior protection against not only HIV but other pathogens such as tuberculosis, malaria, the hepatitis C virus, influenza and the pandemic coronavirus strain as well, Pulendran told Stanford Medicine News.

Combination shot of insulin and amylin for diabetics

A combined two-in-one injection consisting of insulin and amylin may help diabetics better control their blood sugar levels, a study published on May 11 in Nature Biomedical Engineering found.

Previously, insulin and amylin a hormone that works with insulin to lower blood sugar levels more effectively than insulin alone could only be injected in two separate shots. Patients who have taken both drugs separately lose weight and have better control over their blood sugar levels. When combined, the drugs were too unstable for a single syringe.

Taking that second injection with the insulin shot is a real barrier for most patients, materials science and engineering assistant professor Eric Appel told Stanford News. Our formulation would allow them to be given together in a single injection or in an insulin pump.

The researchers developed a protective coating called cucurbituril-PEG that surrounds the insulin and amylin, allowing both to coexist in a single shot. The findings suggest the coating increases stability, promoting the drug shelf life.

Were excited about the results to say the least, Appel told Stanford News.

Genetic evolution of hybrid populations

Scientists have identified the cause of melanoma in hybrid fish in Mexico, a study published on May 14 in Science reports.

The highland swordtails and sheepshead swordtails have interbred for many generations and are native to Mexico, creating a population of hybrids. Researchers have identified two genes responsible for melanoma, which often develops in the tails of the male fish.

This discovery marks only the second time a dysfunction in hybrids has been traced to a specific gene in vertebrates. Hybrid offspring of two different species typically have genetic shortcomings.

Were just realizing that hybridization affects species all across the tree of life, including our own species many of us carry genes from Neanderthals and Denisovans, biology assistant professor Molly Schumer told Stanford News. Understanding hybridization and the negative and positive effects that can come from genes that have moved between species is important in understanding our own genomes and those of other species with which we interact.

The findings suggest the genes cd97 and xmrk are responsible for causing melanoma in the fish hybrids.

When I started my PhD in 2011, it was really not accepted that hybridization was common in animals. The best-known examples were mules and fruit flies. Its been such a massive shift and a fun time to be working on this question, Schumer told Stanford News. What weve arrived at now is the best kind of project in science: one that raises way more questions than answers and spins you off in a bunch of different directions.

Contact Derek Chen at derekc8 at stanford.edu.

Read the original post:
Research Roundup: HIV vaccination, diabetes two-in-one injection, hybrid fish genetics - The Stanford Daily

COLUMBUS, Ohio--(BUSINESS WIRE)--Deep Lens, a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials, has integrated proprietary molecular data parsing and management technology into the companys award-winning clinical trial screening and enrollment platform, VIPER. This breakthrough integration will enable cancer care teams, clinical trial sponsors, and trial coordinators to immediately and automatically match patients based on the genetic profile of their cancers to the best precision therapies and oncology clinical trials.

The company worked with the University of Miami Office of Technology Transfer to exclusively license the technology. A team from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and UHealth Information Technology developed an engine to leverage new ways of consuming and normalizing molecular genetic test results from companies, such as Caris Life Sciences, Foundation Medicine, Guardant Health, NeoGenomics, Tempus, and more, to automate and expedite the patient screening process.

Our office facilitates transfer of university innovations for the benefit of the university community and the public, said Bin Yan, Ph.D., J.D., Director of the Office of Technology Transfer. So, it was a natural fit to work with Deep Lens and integrate our two differentiated technologies to solve a real problem in clinical trial recruitment: limited time and resources for physicians and care teams.

In the past, the genetic test results were sent to healthcare providers, where a trained specialist or physician would analyze the results for therapy decisions. But, clinical trial coordinators often do not have access to this data or the ability to extract information from it when matching patients to clinical trials, leading to inconsistencies in the screening process and missed opportunities to leverage the data. Now, with integration into the VIPER platform, molecular test results from any lab vendor, across all patients can be quickly searched and easily analyzed by cancer care teams and clinical trial coordinators immediately and automatically match patients to the best precision-based clinical trials available.

Deep Lens VIPER has already made a big improvement to the patient screening process for our precision trials, said Jim Langford, Vice President of Clinical Operations, Aivita Biomedical in Irvine, California. With the addition of automated molecular-based patient matching, we see VIPER giving us much greater granularity into how we work with our provider sites to drive greater patient engagement.

The collaboration between Deep Lens and the University of Miami not only provides Deep Lens with additional, differentiated technology in precision medicine but establishes the University of Miami as a collaboration partner for future genomics technology development and project work.

Integrating this molecular data parsing and management technology into VIPER and continuing to work with University of Miami on integrating future genomics advancements will ensure that we have the leading and most up-to-date information and technologies, stated TJ Bowen, Ph.D., co-founder and Chief Scientist at Deep Lens. Now, cancer care teams, clinical trial sponsors, and trial coordinators can leverage an AI-enabled workflow platform that aggregates all relevant data sources for even faster automation and improved patient matching to increase clinical trial enrollment.

Patient recruitment for clinical trials remains a time-intensive, costly barrier to the execution of drug development programs. More than 14,000 oncology clinical trials are actively recruiting patients; yet estimates put the rate of participation as low as three percent of potential trial candidates, which can lead to enrollment delays of months, if not years.

"With this new functionality, VIPER will facilitate even greater patient access to cutting-edge treatments. By identifying eligible patients for clinical trials based on their digital and molecular biomarkers, VIPER is exactly what is needed to improve trial enrollment numbers, said David Braxton, M.D., Head of Molecular Pathology at a California cancer center that uses the VIPER platform. Patients deserve access to the most promising treatments and getting access should not be a burden for care teams and patients."

About Deep Lens

Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials. By identifying patients at the time of diagnosis and combining lab, EMR and genomic data, VIPER, Deep Lens integrated cloud platform, provides care teams with visibility and workflows to accelerate recruitment and compress study timelines to bring game-changing therapies to market sooner. Growing with sponsors, providers and strategic partners, Deep Lens challenges the status quo so that patients can get the therapies they want and deserve. For more information, visit deeplens.ai.

See original here:
Deep Lens First to Integrate Cancer Genetic Data into AI Platform to Rapidly Match Patients to Precision Therapies and Clinical Trials - Business Wire

Arthur Gutowski and his son, Arthur Jr., share not only a name, but a rare hereditary blood vessel disorder that can cause severe nosebleeds, costing them as much as a cup of blood at a time.

My mom and uncle had nosebleeds, my grandma had nosebleeds, I have nosebleeds, says Gutowski, 72, of Dearborn, Mich. All three of his sons, including the eldest, who goes by AJ, have or had experienced them as well. (Chris the middle son, passed away in 2012.)

The Gutowskis have hereditary hemorrhagic telangiectasia (HHT), a disorder characterized by nosebleeds and fragile blood vessels. Its also known as Osler-Weber-Rendu disease.

Not a lot of physicians know about HHT, says their mutual doctor, Jeffrey Terrell, M.D., a professor of otolaryngology (also known as an ENT, for ear, nose and throat) at Michigan Medicine, so an estimated 90% of people with it go undiagnosed.

Terrell hopes to change that as Michigan Medicine becomes the states first designated HHT Treatment Center. The honor comes from Cure HHT, a nonprofit dedicated to finding a cure for the disease, and the CDC.

It means an integrated team of HHT experts including genetic counselors, ENTs, hematologists and interventional radiologists work together to provide the highest level of care to help patients manage their HHT.

Patients used to drive to Cleveland or Minnesota to go to such a Center but they have one much closer now, Terrell says.

The designation came with the help of a research grant Michigan Medicine hematologist Suman Sood, M.D. received from the Department of Defense and the CDC that combines treating people with HHT and hemophilia, an inherited disorder where the blood cant clot because of missing proteins in the blood.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

HHT is a gene mutation that causes blood vessels to form abnormally. While the cure remains elusive, it affects about 1 in 5,000 to 1 in 10,000 people. For the Gutowski family, it had a 100% frequency rate.

The nosebleeds experienced by the Gutowski family and others with the disorder frequently causes their hemoglobin numbers to plummet from a healthy adult male range of 12-18 to 4-6, making them tired, dizzy, short of breath and anemic. Before they started seeing Terrell, simple triggers for bleeds were yawning, sneezing and bending over to tie their shoes.

I learned to sneeze with my mouth, AJ says. So does his father.

AJ was in sixth grade taking a quiz when he believes he got his first nose bleed, which is a typical age for the disease to emerge. I knew at the time something was off but I knew my dad and grandma had nose bleeds, too, says AJ, 51, also of Dearborn. It was his normal.

HHT patients tend to have two types of blood vessel abnormalities. The smaller ones emerge on the skin, appearing as red or purple dots the size of a pinhead or elaborate spider veins. Theyre called telangiectasia and are found on the hands, face, mouth lips or inside the nose. The larger blood vessel abnormalities, arteriovenous malformation (AVMs), hide elsewhere in the body, but favor the nose, lungs, gastrointestinal tract, brain and liver. They can be life threatening. The brain AVM, for instance, can cause a stroke. The Gutowskis have liver and gastrointestinal AVMs, along with telangiectasia.

HHT evolves through the years. At first, the elder Gutowskis only symptom was nosebleeds and another spot on his liver, but when he started getting tired all the time, Terrell and his Michigan Medicine colleagues, including Sood and gastroenterologist Neil Sheth, M.D., looked closer. Gutowski had new AVMS in his gastrointestinal tract and they were bleeding.

Sheth used laser treatments to stop the flow and Sood gave Gutowski iron transfusions so he could resume his active life. For his nose vessels, he is on Avastin, a chemotherapy drug thats a vascular growth inhibitor.

For a while there he quit doing everything and was mostly housebound because he was out of breath and extremely fatigued by his anemia, Terrell explains. This past summer he went Up North to fish and travel around. His treatment was life changing.

Gutowski agrees. The U of M doctors are great, he says.

AJ likes having access to the HHT team of doctors, too. He recently had a procedure to blast a kidney stone and they monitored him with extra vigilance because of his tendency to bleed.

Of all the Gutowskis, AJ has long been the most proactive about his care. He keeps up on advancements and raises funds through his volunteer involvement with Cure HHT. He also drives to Washington University in St. Louis where they have an HHT Center for Excellence. Because he has a long relationship with them, he believes hell continue to drive eight hours to get his suggested three year scans to make sure his AVMs have remained the same or that no new ones have emerged. In fact, theyre the ones who noticed his kidney stone during an abdominal scan.

But having an HHT Center closer to home is comforting, too.

Dr. Terrell approached me about the new treatments and we talk about the risks and benefits, AJ says. I think actually over time, I've gotten more effective treatments with much less side effects under Dr. Terrells care, something he expects to continue as Terrell and the Centers team explore newer, emerging treatments.

Having the same doctor as his father is an advantage, too, AJ says.

Like Podcasts? Add the Michigan Medicine News Breakto your Alexa-enabled device orsubscribe for daily updates oniTunes,Google PlayandStitcher.

Were able to talk to each other about our care and sometimes we go in together, AJ says.

It's probably been helpful for the doctors to some extent, too, because they see how the disease is working in both of us. And they're able to connect dots a little bit easier, which translates to better care for both of them.

If you suspect HHT or have been diagnosed with HHT and want to meet with a Michigan Medicine specialist, contact a patient care coordinator at (734) 936-6393.

Go here to see the original:
New HHT Center Gives Hope to Father and Son with Rare Genetic Disease - Michigan Medicine

An analysis of data from over 100 studies including 266,000 women has unearthed 32 previously undiscovered areas in the genome where DNA variation appears to influence a womens risk for developing breast cancer.

The multinational research used information collected by the UK-based Breast Cancer Association Consortium over the last 15 years. New methods were used in the analysis that identified variants that can have different effects for different types of cancer.

The findings from this analysis enhance our understanding of the biology that differentiates subtypes and may improve our ability to predict womens breast cancer risks, even at the level of specific breast cancer subtype, commented Nilanjan Chatterjee, PhD, a professor at Johns Hopkins Bloomberg School of Public Health and one of the lead researchers on the study, which was published in the journal Nature Genetics.

Breast cancer is one of the most common cancers and over 250,000 women are diagnosed every year in the US alone, with 40,000 succumbing to the disease annually. Having a better method of assessing risk is therefore crucial to help assess screening needs and also to better personalize treatment if women develop the disease.

These new variants, add to more than 170 previously discovered genetic variants that influence risk for breast cancer. Of the 32 identified by the researchers to be linked more generally to breast cancer risk, seven were associated with estrogen receptor statusoverexpression of estrogen receptors are seen in 70% of breast cancer cases; seven to the grade of the tumor; four to HER2 receptor statusthe HER2 gene is often mutated in breast cancers and around 30% of treatments target this protein; and two to progesterone receptor status.

Five of the newly discovered variants seemed to be linked to a greater risk for some types of breast cancer, but a lower risk of others.

These variants are special and if followed up properly may lead to important insights into the biology of these breast cancer subtypes, commented Chatterjee.

A key difference between this study and previous similar analyses was that earlier studies have focused on assessing overall risk for developing breast cancer, or looked at some subtypes with relatively simple genetics, such as the BRCA1/2 mutations that dramatically increase a womans risk for developing breast cancer. This study used a technique that allowed them to assess genetic associations with the new variants in the presence of a lot of different background characteristics such as known presence of other genetic variants and other environmental factors.

Although this analysis was very large, including 142,798 breast cancer cases and 123,283 controls, the large majority of women were of European ancestry. Chatterjee and his colleagues plan to replicate their research in even larger, more ethnically diverse populations in future to try and pinpoint additional mutations that might not be present in European populations.

See the original post here:
Analysis of 100 Studies Reveals 32 New Sites of Genetic Variation Linked to Breast Cancer - Clinical OMICs News

Mithua Ghosh, Director Clinical Diagnostics, HOD- Molecular and Clinical Genomics (HCG), Strand life Sciences gives an insight on how genetic testing can help estimate the risk of developing ovarian cancer

Dipti (name changed), a 29-year-old woman presented herself with persistent pelvic pain. Further examinations revealed that she had a large mass in her right ovary. With appropriate investigations, it was diagnosed to be ovarian cancer. She was immediately admitted to the hospital for surgery and subsequent treatment to manage the condition. During her treatment, she was counselled by the genetic counsellor who found a history of ovarian cancer in her family. On the maternal side, her grandmother and great grandmother were diagnosed with ovarian cancer. Based on the family history and early onset of the disease, the counsellor recommended genetic testing for Hereditary Breast and Ovarian Cancer syndrome (HBOC). The report revealed a pathogenic heterozygous mutation in the BRCA1 gene (BReast CAncer one gene). After Diptis reports revealed the BRCA1 mutation, her family members were also advised to undergo genetic counselling and confirmatory tests as precautionary measures towards inherited disorders. Her mother and brother were screened, and the same mutation in the BRCA1 gene was detected in them too. As a preventive measure, Diptis mother opted for a risk-reducing mastectomy, while her other family members were suggested to be under stringent monitoring and surveillance and report any persistent symptoms.

Germline mutations, also known as hereditary mutations, in BRCA1 and BRCA2 genes are associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC) predisposition. Individuals with mutated BRCA1 and BRCA2 genes have an increased risk of developing breast cancer, ovarian cancer (including fallopian and primary peritoneal cancers) and to a lesser extent, other cancers as well. It should be noted that HBOC caused due to pathogenic mutation in the BRCA1 gene shows an autosomal mode of inheritance, i.e. one copy of the faulty gene in an individual is sufficient to increase the risk of developing cancer. These mutations may pass from parents to the next generation, and each first-degree relative (siblings and offspring) has a 50 per cent chance of having this gene alteration.

In India, most of the ovarian cancer cases are diagnosed after they have progressed to advanced stages. Initial symptoms are mistaken and overlooked as regular feminine health issues. Studies show that the survival rate of patients diagnosed with ovarian cancer is approximately 45 per cent. Such low success rates attributed to ovarian cancer is due to late diagnosis. Almost 56.per cent of the ovarian cancer cases are diagnosed when the disease has progressed to advanced stages, which makes it difficult to manage.

A number of tests have been evaluated as potential methods of screening for ovarian cancer. Screening is recommended to start at 30-35 years of age with transvaginal ultrasounds and the blood test for the serum marker CA-125 every 6-12 months. Screening for ovarian cancer in women with family history plays an important role in identifying high-versus average-risk women. An individuals lifetime risk of developing ovarian cancer is influenced by many factors, which include the age, family history, relationship to an already diagnosed family member, etc. In those cases, risk-reducing salpingo-oophorectomy (removal of ovaries and fallopian tubes) is recommended around 35-40 years of age or once childbearing is completed.

Genetic counselling provides a flawless knowledge about the disease condition, surveillance, genetic testing availability and implications along with proper management and risk mitigation strategies. Genetic testing helps to detect gene mutations that predispose an individual to develop ovarian cancer, and thus identify at-risk individuals who require effective monitoring, surveillance and risk management strategies. Creating ovarian cancer awareness among women and encouraging them to go for regular screening can lead to early diagnosis of the disease, which in turn can significantly improve the survival rates with a good quality of life.

Therefore, genetic counselling and genetic testing should be strongly considered in patients with ovarian cancers, particularly if it is an early-onset disease and in the case of family history. This approach unfolds the genetic background of the patient as well the family members to a greater extent and identifies the risk of predisposition to the disease. It also enables the expanded collaborative role in patient care to support the patients and their family members through effective monitoring and surveillance programme and adoption of simple lifestyle changes, and mitigate the risk significantly.

Cancer is no longer a deadly disease; rather, it is a chronic lifestyle disease, which can be treated and effectively managed through early detection.

View original post here:
Ovarian cancer: Genetic testing is need of the hour - Express Healthcare

May 19 (UPI) -- African-American and white women share several genetic mutations that increase risk for breast cancer, according to a study published Tuesday by the Journal of the National Cancer Institute.

Researchers at Boston University and the Mayo Clinic found that mutations of the BRCA1, BRCA2 and PALB2 genes, which are known to raise breast cancer risk in white women, including those of Ashkenazi Jewish descent, are also found in African-American women with the disease.

The genetic mutations have been associated with a more than seven-fold higher risk of breast cancer, the researchers noted.

"We also found that mutations in PALB2, RAD51C and RAD51D confer increased risks of estrogen receptor negative breast cancer in the African-American population," study co-author Fergus Couch, the Zbigniew and Anna M. Scheller Professor of Medical Research at the Mayo Clinic, said in a statement.

About one out of every eight women in the United States will develop invasive breast cancer during their lifetimes, according to BreastCancer.org. African-American women tend to be diagnosed at a younger age and are more likely to die from the disease.

However, rates of breast cancer genetic testing are substantially lower in African-American women than in white women, the authors of the JNCI study said. Differences in health recommendations given to African-American women have been identified as one of the drivers of this disparity, they added.

For the study, Couch and his colleagues sequenced germline DNA from 5,054 African-American women with breast cancer and 4,993 age-matched African-American women without cancer, looking for mutations in 23 genes believed to predispose women to the disease. The researchers then estimated the risk of developing breast cancer associated with having a mutation in any of the genes.

They found that more than 7 percent of women with breast cancer, regardless of race, had a mutation in one of the genes, as compared with 2 percent of the controls. Among women with breast cancers that lacked estrogen receptors -- or had estrogen receptor negative breast cancer -- more than 10 percent had a mutation in one of these genes.

In comparison, 5 percent of women with estrogen receptor positive breast cancer had a mutation in the cancer-related genes.

In addition to common mutations of the BRCA1, BRCA2, PALB2, RAD51C and RAD51D, the authors identified four other genetic mutations associated with a more moderate increase in risk for breast cancer among the women in the study. Previous studies of women of African ancestry were too small to identify genetic mutations other than those affecting BRCA1 and BRCA2.

Based on these findings, testing for breast cancer predisposition genes can prevent breast cancer deaths -- both in women who have never had breast cancer and in women with breast cancer -- according to the researchers.

"The multi-gene panels that are currently available to test women diagnosed with breast cancer or women at high risk due to their family history will be useful for African American women," said co-author Julie Palmer, director of Boston University's Slone Epidemiology Center.

"Depending on results of the testing and an individual's own weighing of pros and cons, a woman with a mutation in any of these genes may choose more aggressive screening for cancer, and women with mutations in the high risk BRCA1 and BRCA2 genes may choose removal of her breasts and/or ovaries as a way to prevent initial breast cancer or recurrence," she added.

See the article here:
African-American, white women share genetic mutations linked to breast cancer - UPI News

In a small pool nestled between two waterfalls in Hidalgo, Mexico, lives a population of hybrid fish the result of many generations of interbreeding between highland and sheepshead swordtails. The lab of Molly Schumer, assistant professor of biology at Stanford University in the School of Humanities and Sciences, has been collecting these fish for years to study the evolution of hybrids.

Two hybrid male swordtail fish representing the extreme versions of the trait these researchers studied. The male on the left has melanoma and the male on the right has only a small spot. (Image credit: Daniel Powell)

Were just realizing that hybridization affects species all across the tree of life, including our own species many of us carry genes from Neanderthals and Denisovans, said Schumer, referring to two ancient human species that interbred with our ancestors. Understanding hybridization and the negative and positive effects that can come from genes that have moved between species is important in understanding our own genomes and those of other species with which we interact.

In a new paper, published May 14 in Science, the researchers pinpoint two genes responsible for a melanoma that often develops near the tails of male highland-sheepshead hybrids. The finding marks only the second time that a hybrid dysfunction has been traced to specific genes in vertebrates. (The only other case where scientists have narrowed hybrid dysfunction in vertebrates down to the single-gene level is in a longstanding hybrid population of mice in Europe and their relatives.)

People have long known that the offspring of two different species tend to have genetic flaws. For example, mules which are donkeys-horse hybrids are infertile. Ironically, in order to find the genes responsible for such dysfunctions, researchers need hybrids that are fit enough to breed for several generations after the initial hybridization. Otherwise, the pieces of their genomes that come from the parental species are so large that it is nearly impossible to trace the influence of any one gene.

Three hybrid swordtail males displaying varying degrees of melanin invasion, from a small spot like spots typically found in sheepshead swordtails (middle) to very advanced melanoma (back). (Image credit: Daniel Powell)

This is what makes the highland-sheepshead hybrids an exceptional case study. They have been interbreeding for about 45 generations, resulting in genomes that contain smaller chunks of parental DNA, which are easier to inspect at a single-gene level.

Weve known about genetic incompatibility between the genes of two species since the 1940s. Despite that, we dont know many of the genes that cause these negative interactions, said Daniel Powell, a postdoctoral fellow in the Schumer lab and lead author of the paper. Our lab has clearly defined natural hybrids and weve developed the genomic resources for both parental species. These fish represent a unique system for addressing this question.

In order to home in on the genes responsible for melanoma in hybrids, the researchers first turned their attention to the pure sheepshead swordtails and the genetic origin of a black spot some of these fish develop which is non-cancerous but found in the same location as the hybrids melanoma. Analyzing the genomes of nearly 400 individual fish, they linked the black spot with the presence of a gene called xmrk. Following that lead, the researchers concluded that xmrk was also more highly expressed in hybrids with melanoma compared to those without it altogether, it could explain 75 percent of all variation in the spotting they studied in both the pure sheepshead and hybrid fishes.

The researchers also found that another gene called cd97 which some hybrids inherit from their highland swordtail ancestors was more highly expressed in the highland swordtails and in hybrids than in sheepshead swordtails. Further genetic evidence suggests that cd97 and xmrk interact in some way to produce melanoma in the hybrids.

Interestingly, even though neither gene is associated with melanoma in the parental swordtails species, theyre both linked to cancer in other animals. In a distantly related swordtail hybrid, for example, xmrk interacts with another gene not cd97 to cause melanoma, and a gene related to cd97 has been associated with cancer in humans.

Taken together, these findings yield a puzzling picture. Weve ended up with competing but not mutually exclusive ideas about hybrid incompatibility and disease, said Powell. Weve lent credibility to the idea that some genes might be vulnerable to breaking down in different species which is surprising, given the randomness of evolution. But we also have evidence for the idea that there is a diversity of genetic causes for similar dysfunctions.

Schumer says she took a bit of a gamble when she focused her studies on hybridization, but her bet is paying off.

When I started my PhD in 2011, it was really not accepted that hybridization was common in animals. The best-known examples were mules and fruit flies. Its been such a massive shift and a fun time to be working on this question, said Schumer, who is senior author of the paper and a member of Stanford Bio-X. What weve arrived at now is the best kind of project in science: one that raises way more questions than answers and spins you off in a bunch of different directions.

Through future work, the researchers want to figure out why hybrid swordtails with melanoma are less likely to survive in the wild and in captivity. They are also curious to know why so many of these fish have the melanoma its possible that, when it comes to mate selection, females prefer males with the large black spots generated by melanoma. Already, they have lined up several ideas to further understand whether genes go wrong in a repeatable way in hybrids, or if what theyve found in xmrk and cd97 is closer to coincidence.

Stanford co-authors of this paper include Schumer lab research staff, Shreya Banerjee and Danielle Blakkan. Additional authors are from Centro de Investigaciones Cientificas de las Huastecas Aguazarca, A.C.; Texas A&M University; Northeastern University; Princeton University; University of Wurzburg; Benemerita Universidad Autonoma de Puebla; Harvard Medical School; the Howard Hughes Medical Institute; the Broad Institute of Harvard and MIT; Columbia University; and Texas State University, San Marcos.

This work was funded by the National Science Foundation, the Hagler Institute for Advanced Study, the Howard Hughes Medical Institute, LOreal for Women in Science, and the National Institutes of Health.

To read all stories about Stanford science, subscribe to the biweeklyStanford Science Digest.

Read more:
Genetic origins of hybrid dysfunction | Stanford News - Stanford University News

Key Takeaways

Hands-On Genetic Algorithms with Python by Eyal Wirsansky is a new book which explores the world of genetic algorithms to solve search, optimization, and AI-related tasks, and improve machine learning models. InfoQ interviewed Eyal Wirsansky about how genetic algorithms work and what they can be used for.

In addition to our interview, InfoQ was able to obtain a sample chapter which can be downloaded here.

InfoQ: How do genetic algorithms work?

Eyal Wirsansky: Genetic algorithms are a family of search algorithms inspired by the principles of evolution in nature. They imitate the process of natural selection and reproduction, by starting with a set of random solutions, evaluating each one of them, then selecting the better ones to create the next generation of solutions. As generations go by, the solutions we have get better at solving the problem. This way, genetic algorithms can produce high-quality solutions for various problems involving search, optimization, and learning. At the same time, their analogy to natural evolution allows genetic algorithms to overcome some of the hurdles encountered by traditional search and optimization algorithms, especially for problems with a large number of parameters and complex mathematical representations.

InfoQ: What type of problems do genetic algorithms solve?

Wirsansky: Genetic algorithms can be used for solving almost any type of problem, but they particularly shine where traditional algorithms cannot be used, or fail to produce usable results within a practical amount of time. For example, problems with very complex or non-existing mathematical representation, problems where the number of variables involved is large, and problems with noisy or inconsistent input data. In addition, genetic algorithms are better equipped to handle deceptive problems, where traditional algorithms may get trapped in a suboptimal solution.

Genetic algorithms can even deal with cases where there is no way to evaluate an individual solution by itself, as long as there is a way to compare two solutions and determine which of them is better. An example can be a machine learning-based agent that drives a car in a simulated race. A genetic algorithm can optimize and tune the agent by having different versions of it compete against each other to determine which version is better.

InfoQ: What are the best use cases for genetic algorithms?

Wirsansky: The most common use case is where we need to assemble a solution using a combination of many different available parts; we want to select the best combination, but the number of possible combinations is too large to try them all. Genetic algorithms can usually find a good combination within a reasonable amount of time. Examples can be scheduling personnel, planning of delivery routes, designing bridge structures, and also constructing the best machine learning model from many available building blocks, or finding the best architecture for a deep learning model.

Another interesting use case is where the evaluation is based on peoples opinion or response. For example, you can use the genetic algorithm approach to determine the design parameters for a web sitesuch as color palette, font size, and location of components on the pagethat will achieve the best response from customers, such as conversion or retention. This idea can also be used for genetic art artificially created paintings or music that prove pleasant to the human eye (or ear).

Genetic algorithms can also be used for ongoing optimizationcases where the best solution may change over time. The algorithm can run continuously within the changing environment and respond dynamically to these changes by updating the best solution based on the current generation.

InfoQ: How can genetic algorithms select the best subset of features for supervised learning?

Wirsansky: In many cases, reducing the number of featuresused as inputs for a model in supervised learningcan increase the models accuracy, as some of the features may be irrelevant or redundant. This will also result in a simpler, better generalizing model. But we need to figure out which are the features that we want to keep. As this comes down to finding the best combination of features out of a potentially immense number of possible combinations, genetic algorithms provide a very practical approach. Each potential solution is represented by a list of booleans, one for each feature.

The value of the boolean (0 or 1) represents the absence or presence of the corresponding feature. These lists of boolean values are used as genetic material, that can be exchanged between solutions when we mate them, or even mutated by flipping values randomly. Using these mating and mutation operations, we create new generations out of preceding ones, while giving an advantage to solutions that yielded better performing models. After a while, we can have some good solutions, each representing a subset of the features. This is demonstrated in Chapter 7 of the book (our sample chapter) with the UCI Zoo dataset using python code, where the best performance was achieved by selecting six particular features out of the original sixteen.

InfoQ: What are the benefits that we can get from using genetic algorithms with machine learning for hyperparameter tuning?

Wirsansky: Every machine learning model utilizes a set of hyperparametersvalues that are set before the training takes place and affect the way the learning is done. The combined effect of hyperparameters on the performance of the model can be significant. Unfortunately, finding the best combination of the hyperparameter valuesalso known as hyperparameter tuningcan be as difficult as finding a needle in a haystack.

Two common approaches are grid search and random search, each with its own disadvantages. Genetic algorithms can be used in two ways to improve upon these methods. One way is by optimizing the grid search, so instead of trying out every combination on the grid, we can search only a subset of combinations but still get a good combination. The other way is to conduct a full search over the hyperparameter space, as genetic algorithms are capable of handling a large number of parameters as well as different parameter types continuous, discrete and categorical. These two approaches are demonstrated in Chapter 8 of the book with the UCI Wine dataset using python code.

InfoQ: How can genetic algorithms be used in Reinforcement Learning?

Wirsansky: Reinforcement Learning (RL) is a very exciting and promising branch of machine learning, with the potential to handle complex, everyday-life-like tasks. Unlike supervised learning, RL does not present an immediate 'right/wrong' feedback, but instead provides an environment where a longer-term, cumulative reward is sought after. This kind of setting can be viewed as an optimization problem, another area where genetic algorithms excel.

As a result, genetic algorithms can be utilized for reinforcement learning in several different ways. One example can be determining the weights and biases of a neural network that interacts with its environment by mapping input values to output values. Chapter 10 of the book includes two examples of applying genetic algorithms to RL tasks, using the OpenAI Gym environments mountain-car and cart-pole.

InfoQ: What is bio-inspired computing?

Wirsansky: Genetic algorithms are just one branch within a larger family of algorithms called Evolutionary Computation, all inspired by Darwinian evolution. One particularly interesting member of this family is Genetic Programming, that evolves computer programs aiming to solve a specific problem. More broadly, as evolutionary computation techniques are based on various biological systems or behaviors, they can be considered part of the algorithm family known as Bio-inspired Computing.

Among the many fascinating members of this family are Ant Colony Optimizationimitating the way certain species of ants locate food and mark the paths to it, giving advantage to closer and richer locations of food; Artificial Immune Systems, capable of identifying and learning new threats, as well as applying the acquired knowledge and respond faster the next time a similar threat is detected; and Particle Swarm Optimization, based on the behavior of flocks of birds or schools of fish, where individuals within the group work together towards a common goal without central supervision.

Another related, broad field of computation is Artificial Life, involving systems and processes imitating natural life in different ways, such as computer simulations and robotic systems. Chapter 12 of the book includes two relevant Python-written examples, one solving a problem using genetic programming, and the otherusing particle swarm optimization.

Eyal Wirsansky is a senior software engineer, a technology community leader, and an artificial intelligence researcher and consultant. Eyal started his software engineering career as a pioneer in the field of voice over IP, and he now has over 20 years' experience of creating a variety of high-performing enterprise solutions. While in graduate school, he focused his research on genetic algorithms and neural networks. One outcome of his research is a novel supervised machine learning algorithm that combines the two. Eyal leads the Jacksonville (FL) Java user group, hosts the Artificial Intelligence for Enterprise virtual user group, and writes the developer-oriented artificial intelligence blog, ai4java.

Continued here:
Q&A on the Book Hands-On Genetic Algorithms with Python - InfoQ.com

Bianca Acevedo

If youve ever been a newlywed, you know the tingly euphoria of saying I do and starting a life with your spouse. This is romantic love, Western style. We often chalk it up to chemistry, an ill-defined connection of hearts and minds. Groundbreaking research at UC Santa Barbara finds we were closer than we knew.

For the first time, researchers have explored the neural and genetic connections to romantic love in newlyweds.

By using functional magnetic resonance imaging (fMRI) and genetic analysis of 19 first-time newlyweds, Bianca Acevedo and her collaborators showed that romantic love maintenance is part of a broad mammalian strategy for reproduction and long-term attachment that is influenced by basic reward circuitry, complex cognitive processes and genetic factors.

In short, were hard-wired to sustain romantic love to maintain a successful marriage and the family unit, thanks to neurotransmitters like dopamine and a suite of genetic mutations.

This is the first study to examine the neural and genetic correlates of romantic love maintenance, said Acevedo, a research scientist at UCSBs Department of Psychological & Brain Sciences and the lead author of After the Honeymoon: Neural and Genetic Correlates of Romantic Love in Newlywed Marriages in the journal Frontiers in Psychology.

The study showed that the maintenance of love is not only associated with activation of subcortical regions, but also higher order centers of the brain, she said. Also, for the first time we provide evidence that the propensity to sustain romantic love may be affected by genetic variability.

Specifically, the genes we examined are associated with pair-bonding behaviors including fidelity and sexual behaviors; and social behaviors such as trust, eye-gazing and attachment.

To test their hypothesis that romantic love is a developed form of the mammalian drive to find and keep mates, the researchers performed fMRI scans of the brains of the members of the study group 11 women and eight men. Participants were shown alternating images of their partners and a neutral acquaintance they knew well.

At the start of each session, the subjects were instructed to recall non-sexual events with the person whose face was displayed. While still in the scanner, participants rated their moods to verify that the evoked emotions corresponded to the target image.

The participants were tested around the time of marriage and a year later.

In addition, they provided saliva samples for testing of vasopressin, oxytocin and dopamine genes implicated in pair bonding in non-human mammals, such as voles.

Our findings showed robust evidence of the dopamine reward systems involvement in romantic love, Acevedo said. This system is interesting because it is implicated in motivation, energy, working for rewards, and is associated with corresponding emotions such as excitement, euphoria and energy, as well as frustration if the drive is thwarted.

Acevedos current research builds on her work on empathy and altruism and its correlates in the brain.

Empathy has its roots in social bonding, she explained. In our previous work we showed that although humans express sentiments such as empathy and altruism towards strangers and non-close others, brain responses to partners are stronger.

Thus, there is specificity. Romantic love is somewhat different in that it may or may not include empathy or altruism, but in healthy partnerships it does.

For some romantics, it might seem a tad clinical to chalk up our feelings of love and commitment to biochemistry. Acevedo, however, said gene mutations and brain activity are only components of romance and belonging.

Humans are creative and clever, she said. Romantic love inspires people to know how to put a smile on their partners face. By making our partners happy we not only keep our relationships stable, but we also derive joy from such events.

In the brain, this is shown as increased reward activation when people are shown images of a partner smiling and they are told that something wonderful has happened to the partner, Acevedo said. People know this intuitively. They know that romance goes a long way in finding and keeping a preferred mate.

Thats why there is multibillion-dollar industry built on it from dating sites, to lingerie to Hallmark cards, chocolate and diamond rings.

And besides, our chemical impulses dont buy flowers or cook dinner.

Love is basic but complex, Acevedo said. We are wired to love, but it takes work to find and keep love alive."

Follow this link:
UCSB Researchers Study Neural, Genetic Links to Romantic Love in Newlyweds - Noozhawk

Welsh patients are set to take part in a groundbreaking study to explore whether a persons genetics may influence their susceptibility to coronavirus.

The GenOMICC study, announced by the Secretary of State for Health and Social Care Matt Hancock on May 13, will involve 20,000 patients who are severely ill with Covid-19 - including 100 from Wales.

These people, many of whom are in intensive care, will have their genetic code studied and compared with those who have much milder symptoms.

The scientists' aim is to understand whether a person's genetics may influence how unwell they can get from the virus.

Researchers claim the data will help improve our knowledge of the virus' varied effects on people and support the search for treatments.

Professor Kieran Walshe, director of Health and Care Research Wales - which is coordinating study set-up and recruitment in Wales - said: "It is vital that we learn as much about Covid-19 as possible so that we can provide the most effective treatments and care for all patients.

"This groundbreaking research may help us to find out why some patients experience a mild infection, while others need intensive care treatment and why some sadly die.

"Through research, we can discover the evidence needed to give all patients the best possible outcome."

Patients are being recruited from Aneurin Bevan, Cardiff and Vale, Cwm Taf Morgannwg, Swansea Bay, Betsi Cadwaladr and Hywel Dda University Health Boards.

The data collected by health boards in Wales and others will be compared to that from a further 15,000 Covid-19 patients who experienced only mild symptoms.

Dr Matt Morgan, Health and Care Research Wales specialty lead for critical care in Wales, said: "We should all be very proud that despite the immense challenges, intensive care units throughout Wales have been leading contributors to research trials aimed at understanding Covid-19.

"Saving lives requires not just ventilators and hospital beds, but high-quality research done collaboratively.

"Without this research, we will not be able to understand, prevent or treat life threatening diseases including Covid-19. Research matters, now more than ever."

The study is being led by the partnership between the GenOMICC Study Consortium, led by the University of Edinburgh, and Genomics England.

Dr Kenneth Baillie, chief investigator on the GenOMICC study, said: "Our genes play a role in determining who becomes desperately sick with infections like Covid-19.

"Understanding these genes will help us to choose treatments for clinical trials. The GenOMICC study has been running since 2016, and has been investigating genetic factors that impact how patients fare in response to a number of severe illnesses.

"Since the beginning of the Covid-19 outbreak, and with the tremendous support of the UK critical care community, the study has expanded and accelerated enormously, and we are now recruiting in over 170 ICUs across the country.

"I am delighted to be working with Health and Care Research Wales to deliver this important work."

Excerpt from:
Wales taking part in groundbreaking genetics study in the fight against coronavirus - Wales Online

Angus Australia's Jen Peart, just appointed in the role of northern development officer.

Angus Australia has appointed Jen Peart in the role of Northern Development Officer.

Through her new role, Jen will be responsible for providing breeding decision support to producers and the beef supply chain in northern Australia using Angus and Angus-influenced genetics. This includes the development of innovative education tools, resources and extension programs.

Jen will be conducting her role based in Central Queensland, north of Injune.

She grew up in Central Queensland on an organic commercial beef cattle property that breeds, backgrounds and finishes composite cattle. After completing a Bachelor of Rural Science at University of New England Armidale she went on to join Meat and Livestock Australia in a variety of roles, most notably as an analyst in the Market Information team and as a Project Officer in Integrity Systems Company, managing the LPA program.

As a result of their involvement in the family business, Jen and her husband have taken the opportunity to move home to Central Queensland to play a more active role in the beef production enterprise.

Building on her background, Jen looks forward to developing her role at Angus Australia, within the Strategic Projects team.

"I am excited to be working to further build on opportunities to benefit the Northern beef supply chain through the use of Angus genetics," she said.

"I am particularly passionate about producer profitability and delivering research and extension of value, and I am eager to work with producers in northern Australia on the opportunities of using Angus and Angus-influenced genetics, coupled with the vast array of objective data, within their beef enterprises."

To contact Jen, please email jen.peart@angusaustralia.com.au or phone her on 0417 219 405.

The story Angus Australia's new northern development officer first appeared on Farm Online.

Read more:
Angus Australia's new northern development officer - Farm Weekly

Express News Service

BENGALURU: While India is waging a virtual bio-war against the Covid virus, and positive cases are inching close to the 1-lakh mark, there is a critical hitch in Indias response so far: Dozens of private research and testing facilities, raring to work on understanding genetic sequencing and mutation patterns, are complaining that they are not able to procure the relevant viral genetic material (RNA/c-DNA) for the purpose of research. Understanding the virus better could help develop testing kits, vaccines or even pharmaceutical anti-virals, say researchers.

Dr Kunal Sharma, head of pathology and member of the Karnataka Covid Consultative Committee, and who is among those credited for starting fever clinics, expressed this frustration. It is more than two-and-half months since the Covid crisis is upon us, and many countries have been able to do better than us simply because of better synergy. Here, there are too many unnecessary restrictions. It is common knowledge that the viral genetic material, once extracted, poses no risk of transmission of the disease. It should be shared widely with appropriate research facilities as it cannot infect anyone, yet there are restrictions that this cannot be shared among research labs. We have lost a lot of precious time grappling with these restrictions.

Here is a sample of the Indian Council of Medical Research (ICMR) official rules: Kindly note that no sharing of sample with any organisation, no amplification of the virus in any cell culture and no sequencing of viral genome from any sample is to be done by any lab.Dr Prabhu Meghanathan, head, surgical pathology, Hybrinomics Life Sciences, explained, These guidelines come as a major hurdle in necessary scientific research to beat this pandemic. A better solution would be for governments to give approval to research facilities which meet government standards, to use genetic material for research on prevention or a cure. We are a research laboratory that would like to work on Covid-19. If the government places restrictions, research will be delayed.

Advocate KV Dhananjay, who practices in the Supreme Court and has been waging a battle to enable India fight Covid better, said, Mindless restrictions do not help anybody. While tiny nations like Israel and South Korea are doing a lot to fight Covid, our nation isnt doing much, though it has great potential. I am pained by the attitude of the bureaucracy, I have written to the ICMR and government of India asking for unnecessary restrictions to be removed so that research can be better directed to fight Covid. If genetic data about the virus is available, researchers can work on producing cheaper testing kits, vaccines or medicines.DyCM C N Ashwath Narayan said, We understand this issue and are aware of it. We will appoint a nodal officer to work with the Centre and labs, to help facilitate better flow of information.

View original post here:
Researchers hoping to work on Covid genetic material run into ICMR rules - The New Indian Express

The emergence of COVID-19 has put a spotlight on the $258 billion biotechnology industry.

Across the globe, companies large and small are racing to develop a vaccine.

After all, an effective vaccine is the only surefire path back to normal.

And, of course, that means big profits for the first to market.

Thats why the minute a headline comes out about a new development, stock prices surge higher. TakeModerna Inc. (Nasdaq: MRNA), for example. Following a report on Monday of positive results in a test on just eight individuals, MRNA stock jumped 20%. That brings the total gains for the stock to over 150% in just two months!

You can see why biotech stocks get a bad reputation as purely speculative plays. Company profits and the fate of stock gains rest solely on the outcome of clinical trials.

But if you dig deeper, you can find companies with broad product portfolios that generate billions in sales and profits.

And the truth is that the biotech industry offers an incredible value opportunity at the moment and thats why you should act now.

Ever since peaking in mid-2015, the Nasdaq Biotechnology Index (NBI) has traded in a range that previously never surpassed its prior high.

But industry profits continued to grow over that time. And the result is that valuations have become cheap especially compared to the broader stock market.

Right now, the price-to-earnings (P/E) ratio on the biotech index is 16.5. Thats below its 10-year average of 16.9.

At the same time, the P/E ratio on the S&P 500 Index is 20.9, which is well above its own 10-year average of 15.9.

That means biotech stocks are trading at a 21% discount to the stock market when, historically, theyve traded at a premium.

And now that this sector is garnering tons of attention, investors are realizing this as well. In fact, the group is being pushed above key price levels.

Check out the chart below to see the price action Im talking about:

(Click here to view larger image.)

This chart shows the price ofiShares Trust Nasdaq Biotechnology ETF (NYSE: IBB)over the past 10 years. IBB is an exchange-traded fund (ETF) that tracks the biotech sector. And as shown by the trend line, stocks in this sector are just now staging a key breakout to new highs.

What makes this breakout even more significant is the price consolidation of the past five years. That means a powerful move higher is in the works.

Cheap valuations coupled with surging momentum make biotech stocks an excellent pick in this frothy stock market.

So act quickly and pick up shares in IBB to profit from biotechs breakout!

Best regards,

Clint Lee

Research Analyst,The Bauman Letter

See more here:
Grab This ETF to Profit From Biotech's Breakout - iShares Biotechnology - Banyan Hill Publishing

Click here to get sample of the premium reporthttps://www.quincemarketinsights.com/request-sample-60943?utm_source=campaign=Pooja/AZ

The report commences with brief information of the globalBiotechnology media, sera and reagentsmarket. This report sets the tone for the rest of the report, providing users the scope of the report. The report includes important facts and statistics on the globalBiotechnology media, sera and reagentsmarket.

A globalBiotechnology media, sera and reagentsmarket is provided in this next section. This involves market introduction and a standard product definitionBiotechnology media, sera and reagents. This section provides readers with market value and year-by-year growth. Annual growth gives readers a wider view of growth patterns during the forecast period.

The report focuses on macro-economic, demand and supply drivers, constraints, and important patterns. In order to better inform the decision-making system of clients, the impact analysis for weighted average model-based growth drivers is present in the report.

The report will be updated on a number of market opportunities, which leadingBiotechnology media, sera and reagentscompanies can benefit from, to provide readers with up-to-date information on the latest developments on the globalBiotechnology media, sera and reagentsmarket. As the healthcare sector develops continuously, it is vital forBiotechnology media, sera and reagentsmanufacturers to develop key business strategies to keep a track of current developments and trends. This section provides detailed insights into the sourcing of raw materials, supply chain, regulatory approvals, price analyses, list of distributors and cost structure.

Considering the broad spectrum of the internationalBiotechnology media, sera and reagentsmarket, QMIs report provides important insights, analysis and forecast segmentation. Data are divided into product type, method, technology and region on the globalBiotechnology media, sera and reagentsmarket. This segment-specific analysis also offers a country-specific forecast taking all key parameters of the globalBiotechnology media, sera and reagentsmarket into consideration.

The last section of the report covers the competitive landscape of the globalBiotechnology media, sera and reagentsmarket to give readers an overview of company analysis and market players. This competitive intelligence is based on the categories of suppliers throughout the entire value chain and their participation in the globalBiotechnology media, sera and reagentsmarket.

QMI is committed to providing its clients with impartial and independent solutions for market research. Each QMI report is assembled after an extensive and comprehensive research. In order to give you the most comprehensive and accurate information, we use a mix of proven and innovative methodology. Primary research, secondary research, business research, focused interviews and social media analysis are our main sources of research.

Get Scope of the actual premium reporthttps://www.quincemarketinsights.com/request-toc-60943?utm_source=campaign=Pooja/AZ

Market Segmentation:

By Type: Media Sera ReagentBy Application: Cancer Research Biopharmaceuticals Regenerative Medicine & Tissue Engineering OthersBy End-User: Biotechnology & Pharmaceutical Companies Academic Institute Research LaboratoryBy Region: North America North America, by CountryUSCanadaMexico North America, by Type North America, by Application North America, by End-User Western Europe Western Europe, by CountryGermanyUKFranceItalySpainThe NetherlandsRest of Western Europe Western Europe, by Type Western Europe, by Application Western Europe, by End-User Asia Pacific Asia Pacific, by CountryChinaIndiaJapanSouth KoreaAustraliaIndonesiaRest of Asia Pacific Asia Pacific, by Type Asia Pacific, by Application Asia Pacific, by End-User Eastern Europe Eastern Europe, by CountryRussiaTurkeyRest of Eastern Europe Eastern Europe, by Type Eastern Europe, by Application Eastern Europe, by End-User Middle East Middle East, by CountryUAESaudi ArabiaQatarIranRest of Middle East Middle East, by Type Middle East, by Application Middle East, by End-User Rest of the World Rest of the World, by CountrySouth AmericaAfrica Rest of the World, by Type Rest of the World, by Application Rest of the World, by End-User

Major Companies:

Key Players:GE Healthcare, Bio-Rad laboratories Inc., Merck KGaA (Sigma Aldrich), Sartorius AG, HiMedia Laboratories Pvt., Ltd, Lonza Group Ltd, Merck & Co., Inc.

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us

Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109,Pune, Maharashtra 411028Phone: +91 706 672 5858/+1 208 405 2835/+91 706 672 4848Email:sales@quincemarketinsights.comWeb:www.quincemarketinsights.com

Read the rest here:
Biotechnology Media, Sera and Reagents Market Study and Future Prospect | Forecast To 2028 - Azizsalon News

Increasingly inexpensive genetic sequencing and engineering tools could upend everything from health care to fuel.

Why it matters: This bio revolution could lead to a world that is more sustainable and even extend human lifespans. But its full extent is dependent on social acceptance and carries serious risks as well.

What's happening: The scientific reaction to COVID-19 illustrates the rapid change in the biological sciences, says Michael Chui, a partner at McKinsey Global Institute (MGI). "For SARS-CoV-2, it took a matter of weeks between identifying the new disease and sequencing it, compared to months for the original SARS virus."

But the response to COVID-19 only scratches the surface of what the bio revolution may make possible.

How it works: The chief driver of these changes is the rapid drop in cost of the tools that enable us to understand and increasingly manipulate the stuff of life, including in our own bodies.

The catch: Because biology is far more regulated than the field of artificial intelligence, the speed of the bio revolution will depend not just on science, but on public attitudes. The MGI report estimates 70% of the total impact could hinge on consumer, societal, and regulatory acceptance.

The bottom line: AI gets much of the attention, but advances in biotechnology are poised to be just as momentous. Put those two fields together and they will transform the world.

Read this article:
A coming bio revolution is poised to change the world - Axios

LGC Biosearch Technologies

All of the product type and application segments of the Agricultural Biotechnology market included in the report are deeply analyzed based on CAGR, market size, and other crucial factors. The segmentation study provided by the report authors could help players and investors to make the right decisions when looking to invest in certain market segments.

The Essential Content Covered in the Agricultural Biotechnology Market Report :

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

The report is a compilation of different studies, including regional analysis where leading regional Agricultural Biotechnology markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Agricultural Biotechnology market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Agricultural Biotechnology markets. It also provides information on lucrative opportunities available in key regional Agricultural Biotechnology markets.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=35624&utm_source=COD&utm_medium=001

Table of Content

1 Introduction of Agricultural Biotechnology Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Agricultural Biotechnology Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Agricultural Biotechnology Market, By Deployment Model

5.1 Overview

6 Agricultural Biotechnology Market, By Solution

6.1 Overview

7 Agricultural Biotechnology Market, By Vertical

7.1 Overview

8 Agricultural Biotechnology Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Agricultural Biotechnology Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/agricultural-biotechnology-market/?utm_source=COD&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Agricultural Biotechnology Market Size, Agricultural Biotechnology Market Trends, Agricultural Biotechnology Market Growth, Agricultural Biotechnology Market Forecast, Agricultural Biotechnology Market Analysis NMK, Majhi Naukri, Sarkari Naukri, Sarkari Result

Our Trending Reports

Mobile Data Protection Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Activated Carbon Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Visit link:
Agricultural Biotechnology Market 2020 Global Overview, Growth, Size, Opportunities, Trends, Leading Company Analysis and Forecast to 2026 - Cole of...

Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.

In contrast to all current vaccination approaches against SARS-Co-V-2, the approach of Mirror Biologics Inc., the US subsidiary of Jerusalem-based Immunovative Therapies Ltd., addresses the phenomenon of viral evolution. In the Journal of Translational Medicine, Michael Har-Noy and collegues describe the companies technical rationale for development of a universal anti-viral vaccine designed to protect immunocompromised humans and eldery adults from COVID-19 and any future novel virus outbreaks.

The patent-pending technology called AlloPriming is designed so that a series of injections of bioengineered Th1-cells, called AlloStim, could provide protection from any future viral infection, including progression of the current outbreak of COVID-19 infection, and any future variants of the causative SARS-CoV-2 virus or the next Disease X. The technology primes the elderly immune system to respond to viruses in the same manner as a healthy younger adult immune system would respond it remodels the aging immune system in order to reverse immunosenescence and protect against chronic inflammations. A Phase I/II clinical protocol has been prepared for testing this concept in healthy adults over 50 years in age and is currently under review by the US FDA.

The major focus for vaccine development against viruses are currently strategies that introduce inactivated whole viruses, or pieces of viruses, or viral genetic material to teach the immune system to make antibodies, which bind to the virus. The aim is to elicit antibodies which neutralize the virus by blocking entry into host cells. According to the authors, allo-priming, which triggers call-based immunity, provides a back-up in case vaccination strategies to elicit neutralising antibody protection fails or fails to protect the vulnerable elderly population.

Allo-priming is performed using activated, intentionally mismatched, ex vivo differentiated and expanded living Th1-like cells (AlloStim) derived from healthy donors. Preclinically, multiple intradermal injections of AlloStimcreated a dominate titer of allo-specific Th1/CD8-T-cytotoxic memory cells in circulation, replacing the dominance of exhausted memory cells of the aged immune system. Upon viral encounter, by-stander activation of the allo-specific memory cells caused an immediate release of interferon gamma (IFN-), stopping viral transcription and leading to by-stander activation of innate cellular effector cells and activation of cross-reactive allo-specific CD8-T-cytotoxic lymphocytes.

A youthful immune response is believed to be most capable of clearance of viral infections before the infection progresses to serious disease", said Reuven or, who co-authored the publication. He sees the approach as complementary to current vaccination approaches. But in deed it is more:

All current vaccination approaches have not been successful in protecting against emergent viruses, such as HIV, hepatitis C, Zika, dengue and the pandemic SARS and MERS coronaviruses, which mutatate and adapt very rapidly to its hosts. In contrast to childhood diseases they will not provide lifelong protection because they are based on an approach viral evolution, which does not occur in pathogens such as measles or other childhood diseases. For this reason, current vaccine technology platforms may not timely produce a protective vaccine against COVID-19 or could result in a vaccine that becomes obsolete after a viral mutation.

What is currently widely ignored: traditional vaccines could make rapidly mutating and adapting pathogens more aggressive. Under normal conditions, viral pathogens never become extremely deadly because they only spread if most of their hosts survive the infection. As vaccines create a selection advantage for viruses, which could enter and reproduce themselves ultrarapidly in the host cell, they might trigger a kind of vaccine-driven evolution, which would make viruses more deadly and devasting as postulated for the case of Marek's disease vaccines a neoplastic disease of poultry.

Lead author Michael Har-Noy commented: "While there is great optimism regarding current clinical trials investigating protective vaccines against COVID-19, there is a very real possibility that none of the vaccine candidates under investigation will prove to provide long-term protection from COVID-19, and some vaccine candidates may even make symptoms worse. Even in the event that an effective vaccine is timely developed, such a vaccine likely would not be as effective in providing protective immunity in the elderly. If allo-priming is proven to work as designed, a single series of shots could protect against the current pandemic as well as any future pandemic.

The rest is here:
Vaccine to protect from any viral infection - European Biotechnology